Molecular diagnostics of thyroid tumors

Archives of Pathology and Laboratory Medicine

Volumn 135, Issue 5, 2011, Pages 569-577

  Nikiforov, Yuri E ^a,b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN;

ADENOCARCINOMA; ARTICLE; CHROMOSOME ABERRATION; GENETICS; HUMAN; MEDLINE; METHODOLOGY; MOLECULAR DIAGNOSIS; MORTALITY; PAPILLARY CARCINOMA; POINT MUTATION; PROGNOSIS; SURVIVAL RATE; THYROID TUMOR; TUMOR RECURRENCE;

ADENOCARCINOMA, FOLLICULAR; CARCINOMA, PAPILLARY; CHROMOSOME ABERRATIONS; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM RECURRENCE, LOCAL; POINT MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; PUBMED; SURVIVAL RATE; THYROID NEOPLASMS;

EID: 79956304968     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (128)

1. Albores-Saavedra J, Henson DE, Glazer E, Schwartz AM. Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype- papillary, follicular, and anaplastic: a morphological and epidemiological study. Endocr Pathol. 2007;18(1):1-7. (Pubitemid 47345617)
2. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295(18):2164-2167.
3. Hodgson NC, Button), Solorzano CC. Thyroid cancer: is the incidence still increasing? Ann Surg Oncol. 2004;11(12): 1093-1097. (Pubitemid 40486656)
4. DeLellis RA, Lloyd RV, Heitz PU, Eng C, eds. Pathology and Genetics of Tumours of Endocrine Organs. Lyon, France: IARC Press; 2004. World Health Organization Classification of Tumours; vol 8.
5. Nikiforov YE. Thyroid tumors: classification and general considerations. In: Nikiforov YE, Biddinger PW, Thompson LDR, eds. Diagnostic Pathology and Molecular Genetics of the Thyroid. Baltimore, MD: Lippincott Williams & Wilkins; 2009:94-102.
6. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the US, 1985-1995 [comment in: Cancer. 1998;83(12):2434-2436
7. J. Cancer. 1998;83(12):2638-2648.
8. Adeniran AJ, Zhu Z, Gandhi M, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol. 2006;30(2):216-222. (Pubitemid 43740191)
9. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63(7):1454-1457. (Pubitemid 36373628)
10. Soares P, Trovisco V, Rocha AS, et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene. 2003;22(29):4578-4580. (Pubitemid 36920701)
11. Frattini M, Ferrario C, Bressan P, et al. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene. 2004;23(44):7436-7440. (Pubitemid 39382146)
12. Nikiforova MN, Lynch RA, Biddinger PW, et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab. 2003;88(5):2318-2326. (Pubitemid 36549913)
13. Garcia-Rostan G, Costa AM, Pereira-Castro I, et al. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res. 2005;65(22):10199-10207. (Pubitemid 41743711)
14. Hou P, Liu D, Shan Y, et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res. 2007;13(4):1161-1170. (Pubitemid 46424056)
15. Ricarte-Filho JC, Ryder M, Chitale DA, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKTI. Cancer Res. 2009;69(11):4885-4893.
16. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicularcell neoplasia. Nat Rev Cancer. 2006;6(4):292-306.
17. de Groot JW, Links TP, Plukker JT, Lips CJ, Hofstra RM. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev. 2006;27(5):535-560. (Pubitemid 44213230)
18. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003;95(8):625-627. (Pubitemid 36553510)
19. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005; 12(2):245-262. (Pubitemid 40896444)
20. Ciampi R, Nikiforov YE. Alterations of the BRAF gene in thyroid tumors. Endocr Pathol. 2005;16(3):163-172. (Pubitemid 41687187)
21. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAFERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116(6):855-867. (Pubitemid 38410730)
22. Knauf JA, Ma X, Smith EP, et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res. 2005;65(10):4238-4245. (Pubitemid 40775662)
23. Trovisco V, Vieira de Castro I, Soares P, et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol. 2004;202(2):247-251. (Pubitemid 38208663)
24. Carta C, Moretti S, Passeri L, et al. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)). Clin Endocrinol (Oxf). 2006;64(1):105-109.
25. Hou P, Liu D, Xing M. Functional characterization of the Tl 799-1801 del and A1799-1816ins BRAF mutations in papillary thyroid cancer. Cell Cycle. 2007;6(3):377-379.
26. Chiosea S, Nikiforova M, Zuo H, et al. A novel complex BRAF mutation detected in a solid variant of papillary thyroid carcinoma. Endocr Pathol. 2009; 20(2):122-126.
27. Basolo F, Torregrossa L, Giannini R, et al. Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J Clin Endocrinol Metab. 2010;95(9): 4197-4205.
28. Ciampi R, Knauf JA, Kerler R, et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest. 2005;115(1):94-101. (Pubitemid 40385509)
29. Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab. 2003;88(9):4393-4397. (Pubitemid 37153748)
30. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88(11):5399-5404. (Pubitemid 37452745)
31. Begum S, Rosenbaum E, Henrique R, Cohen Y, Sidransky D, Westra WH. BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Mod Pathol. 2004;17(11):1359-1363. (Pubitemid 39472990)
32. Nikiforova MN, Nikiforov YE. Molecular diagnostics and predictors in thyroid cancer. Thyroid. 2009;19(12):1351-1361.
33. Chung KW, Yang SK, Lee GK, et al. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area. Clin Endocrinol (Oxf). 2006;65(5):660-666. (Pubitemid 44583829)
34. Seethala RR, Nikiforov YE. Anaplastic (undifferentiated) carcinoma. In: Nikiforov YE, Biddinger PW, Thompson LDR, eds. Diagnostic Pathology and Molecular Genetics of the Thyroid. Philadelphia, PA: Lippincott Williams & Wilkins; 2009:228-248.
35. Nikiforov YE, Steward DL, Robinson-Smith TM, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab. 2009;94(6):2092-2098.
36. Pizzolanti G, Russo L, Richiusa P, et al. Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/FTC rearrangement. Thyroid. 2007;17(11):1109-1115. (Pubitemid 350207747)
37. JO YS, Huang S, Kim YJ, et al. Diagnostic value of pyrosequencing for the BRAF V600E mutation in ultrasound-guided fine-needle aspiration biopsy samples of thyroid incidentalomas. Clin Endocrinol (Oxf). 2009,70(1):139-144.
38. Cohen Y, Rosenbaum E, Clark DP, et al. Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin Cancer Res. 2004;10(8):2761-2765. (Pubitemid 38509152)
39. Salvatore G, Giannini R, Faviana P, et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2004;89(10):5175-5180. (Pubitemid 39391466)
40. Kim SK, Kim DL, Han HS, et al. Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules. Diagn Mol Pathol. 2008;17(2):118-125.
41. Jin L, Sebo TJ, Nakamura N, et al. BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagn Mol Pathol. 2006; 15(3): 136-143. (Pubitemid 44325474)
42. Kim SW, Lee JI, Kim JW, et al. BRAFV600E mutation analysis in fineneedle aspiration cytology specimens for evaluation of thyroid nodule: a large series in a BRAFV600E-prevalent population. J Clin Endocrinol Metab. 2010; 95(8):3693-3700.
43. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007;28(7):742-762. (Pubitemid 350294294)
44. Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005; 90(12):6373-6379. (Pubitemid 41759286)
45. Kim TY, Kim WB, Rhee YS, et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf). 2006;65(3):364-368.
46. Kebebew E, Weng J, Bauer J, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer [discussion in: Ann Surg. 2007;246(3):470-4711.
47. Ann Surg. 2007;246(3):466-470.
48. Elisei R, Ugolini C, Viola D, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab. 2008;93(10):3943-3949.
49. Xing M, Clark D, Guan H, et al. BRAF mutation testing of thyroid fineneedle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer.; Clin Oncol 2009;27(18):2977-2982.
50. Rodolico V, Cabibi D, Pizzolanti G, et al. BRAF V600E mutation and p27 kipl expression in papillary carcinomas of the thyroid
51. Lee X, Gao M, Ji Y, et al. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol. 2009;16(2):240-245.
52. Lupi C, Giannini R, Ugolini C, et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92(11):4085-4090. (Pubitemid 350074715)
53. Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas MA, Nistal M, Santisteban P. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr Relat Cancer. 2006; 13(1):257-269.
54. Durante C, Puxeddu E, Ferretti E, et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab. 2007;92(7):2840-2843. (Pubitemid 47037399)
55. Yip L, Nikiforova MN, Carty SE, et al. Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery. 2009; 146(6):1215-1223.
56. Xing M. Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol. 2010;321(1):86-93.
57. Fusco A, Grieco M, Santoro M, et al. A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature. 1987;328(6126): 170-172. (Pubitemid 17108219)
58. Grieco M, Santoro M, Berlingieri MT, et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell. 1990;60(4):557-563.
59. Nikiforov YE. RET/PTC rearrangement in thyroid tumors. Endocr Pathol. 2002;13(1):3-16. (Pubitemid 34665111)
60. Tallini G, Asa SL. RET oncogene activation in papillary thyroid carcinoma. Adv Anat Pathol. 2001;8(6):345-354.
61. Santoro M, Dathan NA, Berlingieri MT, et al. Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Oncogene. 1994;9(2):509-516. (Pubitemid 24041530)
62. Jhiang SM, Sagartz JE, Tong Q, et al. Targeted expression of the ret/FTC1 oncogene induces papillary thyroid carcinomas. Endocrinology. 1996;137(1): 375-378. (Pubitemid 26005013)
63. Santoro M, Chiappetta G, Cerrato A, et al. Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. Oncogene. 1996; 12(8): 1821-1826. (Pubitemid 26146307)
64. Powell DJ Jr, Russell J, Nibu K, et al. The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. Cancer Res. 1998;58(23): 5523-5528. (Pubitemid 28551140)
65. Zhu Z, Ciampi R, Nikiforova MN, Gandhi M, Nikiforov YE. Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. J Clin Endocrinol Metab. 2006;91(9):3603-3610. (Pubitemid 44402144)
66. Unger K, Zitzelsberger H, Salvatore G, et al. Heterogeneity in the distribution of RET/PTC rearrangements within individual post-Chernobyl papillary thyroid carcinomas. I Clin Endocrinol Metab. 2004;89(9):4272-4279. (Pubitemid 39244425)
67. Nikiforova MN. Principles of molecular diagnostics in thyroid samples. In: Nikiforov YE, Biddinger PW, Thompson LDR, eds. Diagnostic Pathology and Molecular Genetics of the Thyroid. Philadelphia, PA: Lippincott Williams & Wilkins; 2009:363-375.
68. Nikiforov YE. RET/PTC Rearrangement - a link between Hashimoto's thyroiditis and thyroid cancer...or not. J Clin Endocrinol Metab. 2006;91(6): 2040-2042. (Pubitemid 43854978)
69. Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, Fagin JA. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res. 1997;57(9):1690-1694. (Pubitemid 27199660)
70. Rabes HM, Demidchik EP, Sidorow JD, et al. Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-Chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clin Cancer Res. 2000;6(3):1093-1103. (Pubitemid 30159372)
71. Fenton CL, Lukes Y, Nicholson D, Dinauer CA, Francis GL, Tuttle RM. The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults.; Clin Endocrinol Metab. 2000;85(3):1170-1175. (Pubitemid 32269367)
72. Soares P, Fonseca E, Wynford-Thomas D, Sobrinho-Simoes M. Sporadic ret-rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms? J Pathol. 1998;185(1):71-78. (Pubitemid 28266719)
73. Bongarzone I, Vigneri P, Mariani L, Collini P, Pilotti S, Pierotti MA. RET/ NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features. Clin Cancer Res. 1998;4(1): 223-228. (Pubitemid 28062900)
74. Tallini G, Santoro M, Helie M, et al. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res. 1998;4(2):287-294. (Pubitemid 28122740)
75. Viglietto G, Chiappetta G, Martinez-Tello FJ, et al. RET/PTC oncogene activation is an early event in thyroid carcinogenesis. Oncogene. 1995;11(6): 1207-1210.
76. Sugg SL, Ezzat S, Rosen IB, Freeman JL, Asa SL. Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. J Clin Endocrinol Metab. 1998;83(11):4116-4122. (Pubitemid 28513605)
77. Saad A, Falciglia M, Steward DL, Nikiforov YE. Amiodarone-induced thyrotoxicosis and thyroid cancer: clinical, immunohistochemical, and molecular genetic studies of a case and review of the literature. Arch Pathol Lab Med. 2004;128(7):807-810. (Pubitemid 38856897)
78. Mayr B, Brabant G, Coretzki P, Ruschoff J, Dietmaier W, Dralle H. ret/ PTC-1, -2, and -3 oncogene rearrangements in human thyroid carcinomas: implications for metastatic potential? J Clin Endocrinol Metab. 1997;82(4):1306-1307. (Pubitemid 27166683)
79. Mochizuki K, Kondo T, Nakazawa T, et al. RET rearrangements and BRAF mutation in undifferentiated thyroid carcinomas having papillary carcinoma components. Histopathology. 2010;57(3):444-450.
80. Sugg SL, Ezzat S, Zheng L, Freeman JL, Rosen IB, Asa SL. Oncogene profile of papillary thyroid carcinoma. Surgery. 1999,125(1):46-52. (Pubitemid 29063170)
81. Cheung CC, Carydis B, Ezzat S, Bedard YC, Asa SL. Analysis of ret/PTC gene rearrangements refines the fine needle aspiration diagnosis of thyroid cancer. J Clin Endocrinol Metab. 2001;86(5):2187-2190. (Pubitemid 32472938)
82. Pizzolanti G, Russo L, Richiusa P, et al. Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF(V600E) mutation and RET/PTC rearrangement. Thyroid. 2007;17(11):1109-1115. (Pubitemid 350207747)
83. Nikiforov Y, Steward DL, Nikiforova MN, et al. Role of molecular testing for mutations improving the fine needle aspiration (FNA) diagnosis of thyroid nodules. Paper presented at: 77th Annual Meeting of the American Thyroid Association; October 11-15, 2006; Phoenix, AZ.
84. Cantara S, Capezzone M, Marchisotta S, et al. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab. 2010;95(3):1365-1369.
85. Moses W, Weng J, Sansano I, et al. Molecular testing for somatic mutations improves the accuracy of thyroid fine-needle aspiration biopsy. World J Surg. 2010;34(11):2589-2594.
86. Namba H, Rubin SA, Fagin JA. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol Endocrinol. 1990;4(10):1474-1479. (Pubitemid 20356608)
87. Karga H, Lee JK, Vickery AL Jr, Thor A, Gaz RD, Jameson JL. Ras oncogene mutations in benign and malignant thyroid neoplasms. J Clin Endocrinol Metab. 1991;73(4):832-836. (Pubitemid 21921945)
88. Hara H, Fulton N, Yashiro T, Ito K, DeGroot LJ, Kaplan EL. N-ras mutation: an independent prognostic factor for aggressiveness of papillary thyroid carcinoma. Surgery. 1994; 116(6):1010-1016. (Pubitemid 24382159)
89. Basolo F, Pisaturo F, Pollina LE, et al. N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression. Thyroid. 2000;10(1):19-23. (Pubitemid 30090361)
90. Ezzat S, Zheng L, Kolenda J, Safarian A, Freeman JL, Asa SL. Prevalence of activating ras mutations in morphologically characterized thyroid nodules. Thyroid. 1996;6(5):409-416. (Pubitemid 26398645)
91. Vasko W, Gaudart J, Allasia C, et al. Thyroid follicular adenomas may display features of follicular carcinoma and follicular variant of papillary carcinoma. Eur] Endocrinol. 2004;151(6):779-786.
92. Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma: an unusually high prevalence of ras mutations. Am J Clin Pathol. 2003;120(1):71-77. (Pubitemid 37046372)
93. Lemoine NR, Mayall ES, Wyllie FS, et al. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene. 1989;4(2): 159-164. (Pubitemid 19096939)
94. Suarez HG, du Villard JA, Severino M, et al. Presence of mutations in all three ras genes in human thyroid tumors. Oncogene. 1990;5(4):565-570.
95. Esapa CT, Johnson SJ, Kendall-Taylor P, Lennard TW, Harris PE. Prevalence of Ras mutations in thyroid neoplasia. Clin Endocrinol (Oxf). 1999; 50(4):529-535. (Pubitemid 29193238)
96. Motoi N, Sakamoto A, Yamochi T, Horiuchi H, Motoi T, Machinami R. Role of ras mutation in the progression of thyroid carcinoma of follicular epithelial origin. Pathol Res Pract. 2000; 196(1): 1-7. (Pubitemid 30046520)
97. Lemoine NR, Mayall ES, Wyllie FS, et al. Activated ras oncogenes in human thyroid cancers. Cancer Res. 1988,48(16):4459-4463.
98. Schark C, Fulton N, Jacoby RF, Westbrook CA, Straus FH II, Kaplan EL. Nras 61 oncogene mutations in Hürthle cell tumors [discussion in: Surgery. 1990; 108(61:999-1000],
99. Surgery. 1990;108(6):994-999.
100. Tallini G, Hsueh A, Liu S, Garda-Rostan G, Speicher MR, Ward DC. Frequent chromosomal DNA unbalance in thyroid oncocytic (Hürthle cell) neoplasms detected by comparative genomic hybridization. Lab Invest. 1999; 79(5):547-555. (Pubitemid 29228213)
101. Garcia-Rostan G, Zhao H, Camp RL, et al. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol. 2003,21(17):3226-3235. (Pubitemid 46606254)
102. Manenti G, Pilotti S, Re FC, Della Porta G, Pierotti MA. Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinomas. Eur J Cancer. 1994;30A(7):987-993. (Pubitemid 24256250)
103. Liu J, Singh B, Tallini G, et al. Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity. Cancer. 2006; 107(6):1255-1264. (Pubitemid 44452774)
104. Fagin JA. Minireview: branded from the start - distinct oncogenic initiating events may determine tumor fate in the thyroid. Mol Endocrinol. 2002;16(5):903-911. (Pubitemid 34478529)
105. Saavedra HI, Knauf JA, Shirokawa JM, et al. The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway. Oncogene. 2000;19(34):3948-3954. (Pubitemid 30658985)
106. Kroll TG, Sarraf P, Pecciarini L, et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science. 2000;289(5483): 1357-1360. (Pubitemid 30656054)
107. French CA, Alexander EK, Cibas ES, et al. Genetic and biological subgroups of low-stage follicular thyroid cancer. Am J Pathol. 2003;162(4):1053-1060. (Pubitemid 36350651)
108. Dwight T, Thoppe SR, Foukakis T, et al. Involvement of the PAX8/ peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors. J Clin Endocrinol Metab. 2003;88(9):4440-4445. (Pubitemid 37153755)
109. Nikiforova MN, Biddinger PW, Caudill CM, Kroll TG, Nikiforov YE. PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am ] Surg Pathol. 2002;26(8):1016-1023.
110. Castro P, Rebocho AP, Soares RJ, et al. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. I Clin Endocrinol Metab. 2006;91(1):213-220. (Pubitemid 43069140)
111. Marques AR, Espadinha C, Catarino AL, et al. Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab. 2002;87(8):3947-3952. (Pubitemid 34879553)
112. Ohori NP, Nikiforova MN, Schoedel KE, et al. Contribution of molecular testing to thyroid fine-needle aspiration cytology of "follicular lesion of undetermined significance/atypia of undetermined significance." Cancer Cytopathol. 2010;118(1):17-23.
113. Delvincourt C, Patey M, Flament JB, et al. Ret and trk proto-oncogene activation in thyroid papillary carcinomas in French patients from the Champagne-Ardenne region. Clin Biochem. 1996;29(3):267-271. (Pubitemid 26142077)
114. Wajjwalku W, Nakamura S, Hasegawa Y, et al. Low frequency of rearrangements of the ret and trk proto-oncogenes in Japanese thyroid papillary carcinomas. Jpn J Cancer Res. 1992;83(7):671-675.
115. Pierotti MA, Bongarzone I, Borello MG, Greco A, Pilotti S, Sozzi G. Cytogenetics and molecular genetics of carcinomas arising from thyroid epithelial follicular cells. Genes Chromosomes Cancer. 1996;16(1):1-14. (Pubitemid 26141248)
116. Musholt TJ, Musholt PB, Khaladj N, Schulz D, Scheumann GF, Klempnauer J. Prognostic significance of RET and NTRK1 rearrangements in sporadic papillary thyroid carcinoma. Surgery. 2000;128(6):984-993.
117. Chevillard S, Ugolin N, Vielh P, et al. Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications. Clin Cancer Res. 2004,10(19):6586-6597. (Pubitemid 39346555)
118. Huang Y, Prasad M, Lemon WJ, et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci USA. 2001;98(26):15044-15049. (Pubitemid 34013966)
119. Giordano TJ, Kuick R, Thomas DG, et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene. 2005;24(44):6646-6656. (Pubitemid 41486795)
120. Chudova D, Wilde JI, Wang ET, et al. Molecular classification of thyroid nodules using high-dimensionality genomic data. J Clin Endocrinol Metab. 2010; 95(12):5296-5304.
121. Tetzlaff MT, Liu A, Xu X, et al. Differential expression of miRNAs in papillary thyroid carcinoma compared to multinodular goiter using formalin fixed paraffin embedded tissues. Endocr Pathol. 2007;18(3):163-173. (Pubitemid 351384379)
122. Pallante P, Visone R, Ferracin M, et al. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer. 2006;13(2):497-508. (Pubitemid 43886672)
123. He H, Jazdzewski K, Li W, et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA. 2005;102(52):19075-19080. (Pubitemid 43049568)
124. Nikiforova MN, Tseng GC, Steward D, Diorio D, Nikiforov YE. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab. 2008;93(5):1600-1608. (Pubitemid 351656494)
125. Visone R, Russo L, Pallante P, et al. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer. 2007; 14(3):791-798. (Pubitemid 350074067)
126. Chen YT, Kitabayashi N, Zhou XK, Fahey TJ III, Scognamiglio T. MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma. Mod Pathol. 2008;21 (9):1139-1146.
127. Weber F, Teresi RE, Broelsch CE, Frilling A, Eng C. A limited set of human microRNA is deregulated in follicular thyroid carcinoma. J Clin Endocrinol Metab. 2006;91(9):3584-3591. (Pubitemid 44402141)
128. Cooper DS, Doherty GM, Haugen BR, et al The American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167- 1214.